InspireMD (NSPR)
Market Price (8/9/2026): $0.7499 | Market Cap: $62.8 MilSector: Health Care | Industry: Life Sciences Tools & Services
InspireMD (NSPR)
Market Price (8/9/2026): $0.7499Market Cap: $62.8 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -62% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 54% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -62% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Geriatric Care, and Targeted Therapies. | Weak multi-year price returns2Y Excs Rtn is -120%, 3Y Excs Rtn is -149% | Penny stockMkt Price is 0.7 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -52 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -481% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 108% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -356%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -370% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -87% Key risksNSPR key risks include [1] substantial going concern risk due to recurring losses and negative cash flows, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -62% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 54% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -62% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Geriatric Care, and Targeted Therapies. |
| Weak multi-year price returns2Y Excs Rtn is -120%, 3Y Excs Rtn is -149% |
| Penny stockMkt Price is 0.7 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -52 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -481% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 108% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -356%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -370% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -87% |
| Key risksNSPR key risks include [1] substantial going concern risk due to recurring losses and negative cash flows, Show more. |
Qualitative Assessment
AI Analysis | Feedback
InspireMD (NSPR) stock has lost about 35% since 4/30/2026 because of the following key factors:
1. Voluntary U.S. Recall of CGuard Prime Delivery System and Withdrawal of Full-Year 2026 Revenue Guidance.
InspireMD initiated a voluntary U.S. recall of its CGuard Prime 135 cm carotid stent delivery system in early May 2026, following a determination during a controlled launch that the technical success of the delivery system in carotid artery stenting procedures did not meet performance expectations. Concurrent with this recall, the company withdrew its prior full-year 2026 revenue guidance of $13 million to $15 million, citing the temporary discontinuation of commercial activity in the U.S.. This decision created significant uncertainty regarding the company's near-term financial performance, with an estimated financial impact including approximately $700,000 in customer-return reserves and $650,000 in inventory impairment costs.
2. Nasdaq Bid Price Deficiency Notice.
In mid-July 2026, InspireMD received a notice from Nasdaq stating that its shares had traded below the $1.00 minimum bid price for 30 consecutive sessions. This triggered a 180-day compliance period to regain compliance, raising concerns among investors about potential delisting and further signaling financial instability for the company.
Show more
InspireMD (NSPR) stock has lost about 35% since 4/30/2026 because of the following key factors:
1. Voluntary U.S. Recall of CGuard Prime Delivery System and Withdrawal of Full-Year 2026 Revenue Guidance.
InspireMD initiated a voluntary U.S. recall of its CGuard Prime 135 cm carotid stent delivery system in early May 2026, following a determination during a controlled launch that the technical success of the delivery system in carotid artery stenting procedures did not meet performance expectations. Concurrent with this recall, the company withdrew its prior full-year 2026 revenue guidance of $13 million to $15 million, citing the temporary discontinuation of commercial activity in the U.S.. This decision created significant uncertainty regarding the company's near-term financial performance, with an estimated financial impact including approximately $700,000 in customer-return reserves and $650,000 in inventory impairment costs.
2. Nasdaq Bid Price Deficiency Notice.
In mid-July 2026, InspireMD received a notice from Nasdaq stating that its shares had traded below the $1.00 minimum bid price for 30 consecutive sessions. This triggered a 180-day compliance period to regain compliance, raising concerns among investors about potential delisting and further signaling financial instability for the company.
3. Persistent Pre-Revenue Stage and Financial Health Concerns.
Despite reporting a 122% year-over-year increase in revenue to $3.4 million for fiscal Q1 2026 (reported May 4, 2026), InspireMD continues to operate at a pre-revenue stage in terms of profitability, posting a net loss of $13.7 million or -$0.16 per share for the quarter. As of July 28, 2026, the company held $41.6 million in cash and marketable securities but also disclosed a "going-concern doubt" alongside a substantial accumulated deficit of $316 million, indicating ongoing reliance on capital markets and an elevated risk of dilution.
Show less
Stock Movement Drivers
Fundamental Drivers
The -37.2% change in NSPR stock from 4/30/2026 to 8/8/2026 was primarily driven by a -47.3% change in the company's P/S Multiple.| (LTM values as of) | 4302026 | 8082026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.18 | 0.74 | -37.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 9 | 11 | 20.8% |
| P/S Multiple | 10.9 | 5.7 | -47.3% |
| Shares Outstanding (Mil) | 83 | 84 | -1.5% |
| Cumulative Contribution | -37.2% |
Market Drivers
4/30/2026 to 8/8/2026| Return | Correlation | |
|---|---|---|
| NSPR | -37.2% | |
| Market (SPY) | 7.6% | 16.7% |
| Sector (XLV) | 13.5% | -8.0% |
Fundamental Drivers
The -53.1% change in NSPR stock from 1/31/2026 to 8/8/2026 was primarily driven by a -61.6% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 8082026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.58 | 0.74 | -53.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 8 | 11 | 39.5% |
| P/S Multiple | 14.9 | 5.7 | -61.6% |
| Shares Outstanding (Mil) | 73 | 84 | -12.3% |
| Cumulative Contribution | -53.1% |
Market Drivers
1/31/2026 to 8/8/2026| Return | Correlation | |
|---|---|---|
| NSPR | -53.1% | |
| Market (SPY) | 12.1% | 17.5% |
| Sector (XLV) | 7.5% | -0.2% |
Fundamental Drivers
The -73.4% change in NSPR stock from 7/31/2025 to 8/8/2026 was primarily driven by a -71.2% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 8082026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.79 | 0.74 | -73.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 7 | 11 | 54.4% |
| P/S Multiple | 19.8 | 5.7 | -71.2% |
| Shares Outstanding (Mil) | 50 | 84 | -40.3% |
| Cumulative Contribution | -73.4% |
Market Drivers
7/31/2025 to 8/8/2026| Return | Correlation | |
|---|---|---|
| NSPR | -73.4% | |
| Market (SPY) | 23.4% | 22.1% |
| Sector (XLV) | 28.7% | 7.0% |
Fundamental Drivers
The -77.8% change in NSPR stock from 7/31/2023 to 8/8/2026 was primarily driven by a -90.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312023 | 8082026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.33 | 0.74 | -77.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 5 | 11 | 107.5% |
| P/S Multiple | 5.2 | 5.7 | 11.0% |
| Shares Outstanding (Mil) | 8 | 84 | -90.3% |
| Cumulative Contribution | -77.8% |
Market Drivers
7/31/2023 to 8/8/2026| Return | Correlation | |
|---|---|---|
| NSPR | -77.8% | |
| Market (SPY) | 74.9% | 8.1% |
| Sector (XLV) | 29.3% | 4.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| NSPR Return | -41% | -72% | 227% | -6% | -32% | -59% | -86% |
| Peers Return | 19% | -20% | -8% | -19% | 37% | -7% | -9% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 105% |
Monthly Win Rates [3] | |||||||
| NSPR Win Rate | 25% | 25% | 58% | 33% | 25% | 25% | |
| Peers Win Rate | 60% | 50% | 48% | 42% | 54% | 38% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| NSPR Max Drawdown | -85% | -75% | -45% | -41% | -56% | -66% | |
| Peers Max Drawdown | -29% | -44% | -49% | -37% | -37% | -43% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: A, TECH, ATEC, CERS, FRNM.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/7/2026 (YTD)
How Low Can It Go
| Event | NSPR | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -28.7% | -9.5% |
| % Gain to Breakeven | 40.3% | 10.5% |
| Time to Breakeven | 239 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -20.3% | -6.7% |
| % Gain to Breakeven | 25.5% | 7.1% |
| Time to Breakeven | 10 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -63.9% | -24.5% |
| % Gain to Breakeven | 177.0% | 32.4% |
| Time to Breakeven | 259 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -57.3% | -33.7% |
| % Gain to Breakeven | 134.3% | 50.9% |
| Time to Breakeven | 328 days | 140 days |
| 2013 Taper Tantrum | ||
| % Loss | -30.7% | -0.2% |
| % Gain to Breakeven | 44.3% | 0.2% |
| Time to Breakeven | 38 days | 1 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -24.5% | -17.9% |
| % Gain to Breakeven | 32.4% | 21.8% |
| Time to Breakeven | 35 days | 123 days |
In The Past
InspireMD's stock fell -4.5% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 4.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | NSPR | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -28.7% | -9.5% |
| % Gain to Breakeven | 40.3% | 10.5% |
| Time to Breakeven | 239 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -20.3% | -6.7% |
| % Gain to Breakeven | 25.5% | 7.1% |
| Time to Breakeven | 10 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -63.9% | -24.5% |
| % Gain to Breakeven | 177.0% | 32.4% |
| Time to Breakeven | 259 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -57.3% | -33.7% |
| % Gain to Breakeven | 134.3% | 50.9% |
| Time to Breakeven | 328 days | 140 days |
| 2013 Taper Tantrum | ||
| % Loss | -30.7% | -0.2% |
| % Gain to Breakeven | 44.3% | 0.2% |
| Time to Breakeven | 38 days | 1 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -24.5% | -17.9% |
| % Gain to Breakeven | 32.4% | 21.8% |
| Time to Breakeven | 35 days | 123 days |
In The Past
InspireMD's stock fell -4.5% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 4.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About InspireMD (NSPR)
InspireMD, Inc. (NSPR) is a medical device company that develops and commercializes innovative solutions for treating vascular and coronary diseases. At its core, the company utilizes a proprietary MicroNet stent platform technology, which forms the basis for its specialized medical devices.
The company's main product offerings include the CGuard carotid embolic prevention system, designed for use in carotid artery procedures to prevent embolic events, and the MGuard Prime embolic protection systems. MGuard Prime is specifically used for patients suffering from acute coronary syndromes, such as heart attacks, and in saphenous vein graft coronary interventions. InspireMD is also actively developing PVGuard, a new MicroNet mesh sleeve and self-expandable stent intended for peripheral vascular applications.
InspireMD serves a global market, with its products being commercialized across Europe, Latin America, the Middle East, and the Asia Pacific region. The company reaches its customer base, which consists primarily of medical professionals and institutions treating vascular and coronary conditions, by selling its specialized medical devices through a network of local distributors.
```AI Analysis | Feedback
Here are 1-3 brief analogies for InspireMD (NSPR):
- Medtronic for embolic prevention stents.
- Abbott Laboratories for specialized carotid and coronary stents.
AI Analysis | Feedback
- CGuard carotid embolic prevention system: A medical device for preventing embolic events in carotid artery applications.
- MGuard Prime embolic protection systems: Systems designed for embolic protection in patients with acute coronary syndromes and during bypass surgery.
- PVGuard: A MicroNet mesh sleeve and self-expandable stent under development for peripheral vascular applications.
AI Analysis | Feedback
InspireMD (NSPR) primarily sells its products to other companies. Based on the provided company description, its major customers are local distributors operating in Europe, Latin America, the Middle East, and Asia Pacific.
The company description does not provide the specific names of these distributor companies.
AI Analysis | Feedback
AI Analysis | Feedback
Marvin Slosman, Chief Executive Officer
Mr. Slosman has over 30 years of experience in the medical device industry, with focused leadership in commercialization and international market development in both public and privately held companies. Prior to joining InspireMD in January 2020, he served as a Business Consultant for Integra LifeSciences, overseeing commercial strategy and market development. He previously served as President of ITAMAR Medical, CEO of Ovalum Vascular, Ltd., a privately held medical device company, and CEO of Phormax Medical, Inc. Mr. Slosman has also held senior commercial leadership positions at Johnson & Johnson, GE Healthcare, and Baxter. His experience includes involvement in IPOs, multiple funding rounds, and M&A transactions.
Michael Lawless, Chief Financial Officer
Mr. Lawless has over two decades of financial leadership experience in the life sciences sector, with a strong track record of driving growth and operational excellence in public companies. Prior to joining InspireMD as Chief Financial Officer (effective on or prior to June 30, 2025), he served as CFO of Lifeward (formerly ReWalk Robotics), a publicly traded medical technology company. Previously, he was the CFO of the $200 million Life Sciences division at Brooks Automation, where he led financial operations and implemented strategies for operational improvements. He possesses deep expertise in capital markets, M&A, investor relations, and financial operations.
Shane Gleason, Chief Commercial Officer
Mr. Gleason brings over 20 years of experience in the medical device industry, having led clinical and commercial operations in both public and privately held companies. Before his promotion to Chief Commercial Officer, he served as InspireMD's General Manager of North America and Vice President of Global Marketing. Prior to joining InspireMD, he was the Vice President of Sales, Vascular Interventions at Surmodics, a medical device company.
Amir Kohen, EVP Finance & Regional Manager
Mr. Kohen has over 20 years of experience in financial and accounting management, including working with global listed companies in the US and Israel. Before joining InspireMD, he spent six years in various management roles at PwC. He holds an MBA in Financial Management.
Sonali Dewan, Vice President of Regulatory & Clinical Affairs and Quality Assurance
Ms. Dewan has over 20 years of global experience in the medical device industry, with leadership roles spanning Regulatory Affairs, Clinical Affairs, and Quality Assurance in both public and privately held companies. Prior to InspireMD, she served as Director of Regulatory Affairs at BlueRock Therapeutics, where she managed global regulatory strategy for drug-device combination products. She also held senior regulatory leadership positions at Medtronic, Johnson & Johnson, Boston Scientific, and St. Jude Medical.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
InspireMD (NSPR) is poised for future revenue growth over the next 2-3 years, driven by several key factors:
- U.S. Commercial Launch and Expansion of CGuard Prime: A significant driver of revenue growth is the commercial launch of the CGuard Prime carotid stent system in the U.S., which began in July 2025 following FDA premarket approval. The company has been strategically building a commercial and operational team to support this major market entry, aiming to establish CGuard Prime as a new standard for carotid intervention.
- Continued Growth in Existing International Markets: InspireMD expects to see ongoing revenue growth from its established markets in Europe, Latin America, the Middle East, and Asia Pacific. The company's CE Mark recertification in 2022 significantly contributed to growth in these OUS (Outside U.S.) markets. InspireMD's CGuard sales in existing markets have already demonstrated consistent increases, with record CGuard revenue reported in Q4 2023.
- Expansion into New International Markets: The company is actively pursuing a strategy of expanding its global distribution footprint by entering new international markets, particularly in the Asia Pacific region. This strategic geographic expansion contributes to increasing market access for its CGuard products.
- Development and Commercialization of New Products: InspireMD has a pipeline of new products beyond CGuard designed to broaden its portfolio, including those for neurovascular and peripheral indications like PVGuard (as mentioned in the background). The company is also progressing with pivotal studies for devices like the SwitchGuard TCAR, with its clearance and launch anticipated by 2027, signaling future product-driven revenue streams.
- Increasing Adoption and Market Share of CGuard/CGuard Prime: InspireMD aims to establish its MicroNet-based CGuard stent platform as the new standard of care for carotid artery disease. The growing body of clinical data and real-world evidence supporting the safety and efficacy of CGuard is expected to drive its adoption by physicians and increase market share globally.
AI Analysis | Feedback
Share Issuance
- In July 2025, InspireMD raised approximately $58 million in combined gross proceeds from an equity private placement of $40.1 million and the exercise of warrants totaling $17.9 million, following FDA premarket approval for its CGuard Prime carotid stent system.
- During the first quarter of 2021, the company completed an upsized underwritten public offering and other capital raising transactions, generating $35.1 million in net proceeds.
- InspireMD regularly issues restricted stock and stock options as inducement grants to new employees and executives, including 40,513 restricted shares in October 2025, 138,442 restricted shares in February 2025, and 677,000 shares and options to its new CFO in June 2025.
Inbound Investments
- A $40.1 million equity private placement in July 2025 was led by existing investors OrbiMed and Marshall Wace, with contributions from new and current investors, and InspireMD board members.
Capital Expenditures
- Operating expenses in Q3 2025 increased by $5.0 million, primarily driven by higher headcount-related expenses and the establishment of a U.S. headquarters.
- In Q2 2025, operating expenses rose by 55% to $13.3 million, largely due to increased headcount and the setup of the U.S. headquarters.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| How Low Can InspireMD Stock Really Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 10.23 |
| Mkt Cap | 1.5 |
| Rev LTM | 815 |
| Op Inc LTM | -2 |
| FCF LTM | -2 |
| FCF 3Y Avg | -8 |
| CFO LTM | 57 |
| CFO 3Y Avg | -5 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 15.1% |
| Rev Chg 3Y Avg | 13.0% |
| Rev Chg Q | 10.0% |
| QoQ Delta Rev Chg LTM | 2.4% |
| Op Inc Chg LTM | 39.1% |
| Op Inc Chg 3Y Avg | 3.9% |
| Op Mgn LTM | -0.7% |
| Op Mgn 3Y Avg | -5.1% |
| QoQ Delta Op Mgn LTM | 1.4% |
| CFO/Rev LTM | 6.9% |
| CFO/Rev 3Y Avg | -2.6% |
| FCF/Rev LTM | -0.7% |
| FCF/Rev 3Y Avg | -5.0% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Develops, manufactures and markets products for the treatment of carotid artery disease and other | 9 | 7 | 6 | ||
| CGuard™ embolic protection system (EPS) | 5 | 4 | |||
| MGuard Prime™ embolic protection system (EPS) | 0 | 0 | |||
| Total | 9 | 7 | 6 | 5 | 4 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Develops, manufactures and markets products for the treatment of carotid artery disease and other | -49 | -32 | -20 |
| Total | -49 | -32 | -20 |
Price Behavior
| Market Price | $0.74 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 04/11/2011 | |
| Distance from 52W High | -71.3% | |
| 50 Days | 200 Days | |
| DMA Price | $0.78 | $1.45 |
| DMA Trend | down | down |
| Distance from DMA | -4.6% | -49.0% |
| 3M | 1YR | |
| Volatility | 58.9% | 56.7% |
| Downside Capture | 226.86 | 197.33 |
| Upside Capture | -7.71 | 16.36 |
| Correlation (SPY) | 15.3% | 20.5% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.57 | 0.07 | 0.39 | 0.54 | 0.83 | 0.30 |
| Up Beta | 0.52 | -0.37 | -0.56 | 0.31 | 0.33 | -0.05 |
| Down Beta | 0.58 | 0.48 | 0.33 | 0.21 | 0.96 | -0.05 |
| Up Capture | 2% | -99% | -67% | -25% | 3% | 9% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 9 | 18 | 24 | 46 | 100 | 311 |
| Down Capture | 116% | 109% | 195% | 159% | 147% | 103% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 13 | 25 | 36 | 65 | 126 | 373 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NSPR | |
|---|---|---|---|---|
| NSPR | -70.5% | 56.6% | -1.94 | - |
| Sector ETF (XLV) | 28.7% | 15.5% | 1.42 | 7.4% |
| Equity (SPY) | 23.3% | 12.8% | 1.36 | 21.2% |
| Gold (GLD) | 28.5% | 28.4% | 0.87 | 13.0% |
| Commodities (DBC) | 32.9% | 19.8% | 1.32 | 2.8% |
| Real Estate (VNQ) | 14.2% | 13.8% | 0.72 | -1.2% |
| Bitcoin (BTCUSD) | -43.7% | 43.0% | -1.21 | 8.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NSPR | |
|---|---|---|---|---|
| NSPR | -27.7% | 70.8% | -0.17 | - |
| Sector ETF (XLV) | 6.2% | 15.0% | 0.23 | 6.8% |
| Equity (SPY) | 13.5% | 17.2% | 0.61 | 12.2% |
| Gold (GLD) | 18.6% | 18.6% | 0.81 | 1.8% |
| Commodities (DBC) | 8.2% | 19.6% | 0.31 | 1.2% |
| Real Estate (VNQ) | 2.3% | 18.9% | 0.02 | 8.1% |
| Bitcoin (BTCUSD) | 9.0% | 53.0% | 0.36 | 6.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NSPR | |
|---|---|---|---|---|
| NSPR | -78.2% | 115.5% | -0.65 | - |
| Sector ETF (XLV) | 10.1% | 16.6% | 0.49 | 5.9% |
| Equity (SPY) | 15.4% | 17.9% | 0.73 | 8.5% |
| Gold (GLD) | 12.1% | 16.2% | 0.61 | 3.7% |
| Commodities (DBC) | 7.4% | 18.0% | 0.33 | 5.9% |
| Real Estate (VNQ) | 4.8% | 20.7% | 0.20 | 4.2% |
| Bitcoin (BTCUSD) | 58.4% | 66.2% | 0.98 | 3.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 7/29/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/4/2026 | -6.0% | 6.8% | -17.9% |
| 3/18/2026 | 0.0% | 0.0% | -24.6% |
| 11/4/2025 | -0.7% | -23.3% | -11.5% |
| 8/5/2025 | -8.2% | -3.4% | -9.0% |
| 5/9/2025 | 0.0% | -8.8% | -7.7% |
| 3/12/2025 | 0.7% | 0.4% | -6.8% |
| 8/6/2024 | 0.7% | -4.1% | -10.5% |
| 5/14/2024 | -0.7% | -5.0% | 9.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 8 | 9 |
| # Negative | 15 | 15 | 14 |
| Median Positive | 0.3% | 2.3% | 9.2% |
| Median Negative | -3.1% | -6.5% | -12.2% |
| Max Positive | 4.4% | 6.8% | 29.5% |
| Max Negative | -14.8% | -23.3% | -24.6% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/4/2026 | -6.0% | 6.8% | -17.9% |
| 3/18/2026 | 0.0% | 0.0% | -24.6% |
| 11/4/2025 | -0.7% | -23.3% | -11.5% |
| 8/5/2025 | -8.2% | -3.4% | -9.0% |
| 5/9/2025 | 0.0% | -8.8% | -7.7% |
| 3/12/2025 | 0.7% | 0.4% | -6.8% |
| 8/6/2024 | 0.7% | -4.1% | -10.5% |
| 5/14/2024 | -0.7% | -5.0% | 9.2% |
| 3/6/2024 | -3.8% | -6.5% | -12.9% |
| 11/6/2023 | -3.0% | -8.9% | -23.1% |
| 8/8/2023 | 0.0% | 1.3% | 12.9% |
| 5/16/2023 | -8.7% | 3.3% | 8.2% |
| 3/30/2023 | -7.8% | -0.9% | -9.6% |
| 11/8/2022 | -14.8% | -12.5% | 12.0% |
| 8/11/2022 | 0.0% | -1.6% | -6.7% |
| 5/10/2022 | 2.1% | 5.2% | 2.4% |
| 3/8/2022 | -1.3% | -6.7% | 24.3% |
| 11/9/2021 | -1.2% | -7.7% | -14.7% |
| 8/10/2021 | -1.8% | -7.1% | 8.6% |
| 5/11/2021 | 4.4% | -3.2% | 29.5% |
| 3/10/2021 | -8.2% | 3.7% | -19.9% |
| 11/9/2020 | -3.1% | 0.3% | 4.3% |
| 8/5/2020 | -2.0% | -6.2% | -19.7% |
| SUMMARY STATS | |||
| # Positive | 8 | 8 | 9 |
| # Negative | 15 | 15 | 14 |
| Median Positive | 0.3% | 2.3% | 9.2% |
| Median Negative | -3.1% | -6.5% | -12.2% |
| Max Positive | 4.4% | 6.8% | 29.5% |
| Max Negative | -14.8% | -23.3% | -24.6% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/18/2026 | 10-K |
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 08/04/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/12/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/05/2024 | 10-Q |
| 03/31/2024 | 05/13/2024 | 10-Q |
| 12/31/2023 | 03/05/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| 09/30/2022 | 11/07/2022 | 10-Q |
| 06/30/2022 | 08/08/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/18/2026 | 10-K |
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 08/04/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/12/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/05/2024 | 10-Q |
| 03/31/2024 | 05/13/2024 | 10-Q |
| 12/31/2023 | 03/05/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| 09/30/2022 | 11/07/2022 | 10-Q |
| 06/30/2022 | 08/08/2022 | 10-Q |
| 03/31/2022 | 05/09/2022 | 10-Q |
| 12/31/2021 | 03/07/2022 | 10-K |
| 09/30/2021 | 11/08/2021 | 10-Q |
| 06/30/2021 | 08/09/2021 | 10-Q |
| 03/31/2021 | 05/10/2021 | 10-Q |
| 12/31/2020 | 03/08/2021 | 10-K |
| 09/30/2020 | 11/09/2020 | 10-Q |
| 06/30/2020 | 08/05/2020 | 10-Q |
| 03/31/2020 | 05/11/2020 | 10-Q |
| 12/31/2019 | 03/10/2020 | 10-K |
| 09/30/2019 | 11/12/2019 | 10-Q |
| 06/30/2019 | 08/05/2019 | 10-Q |
Recent Forward Guidance
Updated 7/27/2026Latest: Q1 2026 Earnings Reported 5/4/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Reserve for customer returns | 0.70 Mil | ||||||
| 2026 Reserve for inventory impairment and remediation costs | 0.65 Mil | ||||||
Insider Activity
Updated 5/29/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Stuka, Paul | Direct | Buy | 5292026 | 0.88 | 20,000 | 17,500 | 584,387 | Form | |
| 2 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 5212026 | 1.01 | 22,778 | 23,006 | 1,064,421 | Form |
| 3 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 5212026 | 1.59 | 2,941 | 4,676 | 1,711,889 | Form |
| 4 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 5212026 | 2.51 | 7,186 | 18,037 | 2,709,799 | Form |
| 5 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 5212026 | 2.51 | 3,760 | 9,438 | 2,727,835 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Stuka, Paul | Direct | Buy | 5292026 | 0.88 | 20,000 | 17,500 | 584,387 | Form | |
| 2 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 5212026 | 1.01 | 22,778 | 23,006 | 1,064,421 | Form |
| 3 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 5212026 | 1.59 | 2,941 | 4,676 | 1,711,889 | Form |
| 4 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 5212026 | 2.51 | 7,186 | 18,037 | 2,709,799 | Form |
| 5 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 5212026 | 2.51 | 3,760 | 9,438 | 2,727,835 | Form |
| 6 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 5212026 | 2.51 | 1,572 | 3,946 | 2,737,273 | Form |
| 7 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 5212026 | 2.51 | 2,482 | 6,230 | 2,741,219 | Form |
| 8 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 5212026 | 3.65 | 10,000 | 36,500 | 3,995,294 | Form |
| 9 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 5212026 | 2.46 | 5,132 | 12,625 | 2,717,318 | Form |
| 10 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 5212026 | 2.51 | 7,073 | 17,753 | 2,785,430 | Form |
| 11 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 5212026 | 2.55 | 9,923 | 25,304 | 2,847,855 | Form |
| 12 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 5212026 | 2.51 | 2,454 | 6,160 | 2,828,090 | Form |
| 13 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 5212026 | 2.46 | 3,660 | 9,004 | 2,777,790 | Form |
| 14 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 5212026 | 2.61 | 2,476 | 6,462 | 2,956,720 | Form |
| 15 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 5212026 | 2.71 | 3,858 | 10,455 | 3,076,714 | Form |
| 16 | Stuka, Paul | Direct | Buy | 5152026 | 1.15 | 5,000 | 5,750 | 745,052 | Form | |
| 17 | Stuka, Paul | Direct | Buy | 5152026 | 1.16 | 10,000 | 11,575 | 744,123 | Form | |
| 18 | Stuka, Paul | Direct | Buy | 5122026 | 1.19 | 10,000 | 11,900 | 753,116 | Form | |
| 19 | Stuka, Paul | Direct | Buy | 5122026 | 1.16 | 65,626 | 76,126 | 722,530 | Form | |
| 20 | Ward, Scott R | Direct | Buy | 5082026 | 1.15 | 73,255 | 84,243 | 272,660 | Form | |
| 21 | Stuka, Paul | Direct | Buy | 5082026 | 1.15 | 6,378 | 7,335 | 611,339 | Form | |
| 22 | Roubin, Gary S | Direct | Buy | 5082026 | 1.18 | 90,000 | 106,200 | 984,684 | Form | |
| 23 | Ward, Scott R | Direct | Buy | 5082026 | 1.15 | 15,995 | 18,394 | 188,417 | Form | |
| 24 | Stuka, Paul | Direct | Buy | 5082026 | 1.12 | 1,517 | 1,699 | 588,248 | Form | |
| 25 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 2022026 | 1.60 | 2,000 | 3,208 | 1,827,240 | Form |
| 26 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 2022026 | 1.63 | 2,900 | 4,730 | 1,861,260 | Form |
| 27 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 2022026 | 1.65 | 5,000 | 8,250 | 1,887,727 | Form |
| 28 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 2022026 | 1.65 | 12,395 | 20,464 | 1,897,126 | Form |
| 29 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 2022026 | 1.66 | 4,781 | 7,956 | 1,932,689 | Form |
| 30 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 2022026 | 1.57 | 8,411 | 13,239 | 1,835,682 | Form |
| 31 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 2022026 | 1.62 | 17,593 | 28,553 | 1,906,480 | Form |
| 32 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 2022026 | 1.59 | 2,955 | 4,710 | 1,900,458 | Form |
| 33 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 2022026 | 1.61 | 2,250 | 3,627 | 1,926,682 | Form |
| 34 | Gleason, Shane Thomas | Chief Commercial Officer | Direct | Sell | 2022026 | 1.58 | 2,909 | 4,593 | 1,890,792 | Form |
| 35 | Stuka, Paul | Direct | Buy | 12112025 | 1.81 | 5,073 | 9,182 | 708,847 | Form | |
| 36 | Stuka, Paul | Direct | Buy | 12082025 | 1.86 | 5,073 | 9,436 | 723,387 | Form | |
| 37 | Stuka, Paul | Direct | Buy | 12052025 | 1.85 | 10,130 | 18,740 | 710,113 | Form | |
| 38 | Stuka, Paul | Direct | Buy | 11132025 | 1.62 | 13,431 | 21,758 | 605,418 | Form | |
| 39 | Roubin, Gary S | Direct | Buy | 8012025 | 2.42 | 41,322 | 99,999 | 1,472,388 | Form | |
| 40 | Kester, Thomas J | Direct | Buy | 8012025 | 2.42 | 30,991 | 74,998 | 1,018,234 | Form | |
| 41 | Slosman, Marvin | CEO and President | Direct | Buy | 8012025 | 2.42 | 10,330 | 24,999 | 5,858,496 | Form |
| 42 | Stuka, Paul | See Footnote | Buy | 8012025 | 2.42 | 20,661 | 50,000 | 1,074,952 | Form |
InspireMD — Investor Video Playlist
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.